Fostroxacitabine bralpamide  (Synonyms: MIV-818)

Fostroxacitabine bralpamide (MIV-818) is an orally active Troxacitabine-based nucleotide proagent. Fostroxacitabine bralpamide has anticancer effects^[1].

Fostroxacitabine bralpamide (MIV-818) is highly metabolized by human hepatocytes, directing high levels of the chain-terminating nucleotide tri-phosphate to the liver. The tri-phosphate is incorporated into DNA during replication, which leads to DNA double strand breaks, DNA damage responses, and cytotoxicity^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

589.37

C₂₂H₃₀BrN₄O₈P

2129993-56-0

O=C1N([C@@]2([H])O[C@H](OC2)COP(OC3=CC=C(C=C3)Br)(N[C@@H](C)C(O[C@@H](C)CCC)=O)=O)C=CC(N)=N1

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. T.R. Jeffry Evans, et al. Phase I study of the novel pro-drug MIV-818 in patients with hepatocellular carcinoma, intra-hepatic cholangiocarcinoma or liver metastases.